Taylor Jonathan Harris, Davis John, Schellhammer Paul
Department of Urology, Eastern Virginia Medical School, Norfolk, VA 23501, USA.
Clin Genitourin Cancer. 2007 Sep;5(6):386-9. doi: 10.3816/CGC.2007.n.021.
Intravesical bacillus Calmette-Guérin (BCG) is a treatment option for superficial (<or=T1) transitional cell carcinoma. Transitional cell carcinoma involving the prostatic urethra presents a treatment dilemma. Whereas prostatic urethral involvement might require radical cystectomy, select patients can be offered BCG and careful surveillance to preserve the bladder. We report long-term experience with BCG in this subset of patients with >5-year follow-up.
Twenty-eight patients with high-risk superficial bladder cancer and prostatic urethral involvement were treated with once-weekly BCG for 6 weeks. Patients with prostatic stromal involvement were excluded. Maintenance was not used before 1995. Currently, we use maintenance BCG after induction. Patients were followed by cystoscopy/cytology and repeat biopsy to detect persistent and/or progressive disease.
After 1 or 2 courses of once-weekly BCG for 6 weeks, 64.3% (18 of 28 of patients) exhibited a complete response in the bladder and prostate at their 6-month followup. Of those obtaining a complete response, 55.6% (10 of 18) experienced recurrence. Three recurrences were in the prostate: 1 isolated and 2 associated with multifocal bladder involvement. Twenty-eight percent (8 of 28 patients) underwent cystectomy because of failure of treatment to eradicate superficial disease or disease progression. Disease-specific survival was 89% (25 of 28 patients) at a median follow-up of 7.5 years.
Our long-term data support the durability of intravesical BCG in select patients with superficial bladder transitional cell carcinoma with prostatic urethral involvement. Follow-up biopsy of the prostatic urethra is mandatory and, if positive, cystectomy is indicated. One third of patients will require cystectomy for persistent or progressive disease; therefore, careful surveillance is critical.
膀胱内灌注卡介苗(BCG)是浅表性(≤T1期)移行细胞癌的一种治疗选择。累及前列腺尿道的移行细胞癌存在治疗难题。虽然前列腺尿道受累可能需要行根治性膀胱切除术,但部分患者可接受卡介苗治疗并进行密切监测以保留膀胱。我们报告了对这一亚组患者进行卡介苗治疗并随访5年以上的长期经验。
28例高危浅表性膀胱癌且累及前列腺尿道的患者接受每周一次的卡介苗治疗,共6周。排除前列腺基质受累的患者。1995年前未使用维持治疗。目前,我们在诱导治疗后使用维持性卡介苗治疗。通过膀胱镜检查/细胞学检查及重复活检对患者进行随访,以检测持续性和/或进展性疾病。
在接受1或2个疗程、为期6周的每周一次卡介苗治疗后,64.3%(28例患者中的18例)在6个月随访时膀胱和前列腺表现为完全缓解。在获得完全缓解的患者中,55.6%(18例中的10例)出现复发。3例复发发生在前列腺:1例为孤立性复发,2例与膀胱多灶性受累相关。28%(28例患者中的8例)因治疗未能根除浅表疾病或疾病进展而接受了膀胱切除术。在中位随访7.5年时,疾病特异性生存率为89%(28例患者中的25例)。
我们的长期数据支持膀胱内灌注卡介苗对部分累及前列腺尿道的浅表性膀胱移行细胞癌患者具有持久疗效。前列腺尿道的随访活检是必要的,若活检结果为阳性,则需行膀胱切除术。三分之一的患者将因持续性或进展性疾病而需要行膀胱切除术;因此,密切监测至关重要。